Nafarelin
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Nafarelin: Ambras type hypertrichosis universalis congenita
One-Sentence Summary
Nafarelin is a GnRH (gonadotropin-releasing hormone) agonist originally used for endometriosis and central precocious puberty. The TxGNN model predicts it may be effective for Ambras type hypertrichosis universalis congenita, but no clinical trials and no publications currently support this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Ambras type hypertrichosis universalis congenita |
| TxGNN Prediction Score | 0.9987 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the compiled data. Based on known pharmacology, nafarelin is a GnRH receptor agonist. After an initial stimulation, it desensitizes the pituitary receptor and suppresses gonadal sex steroids. This explains its use in endometriosis and central precocious puberty.
Ambras syndrome is a congenital genetic disorder of hair growth with no established hormonal driver. The plausibility of a GnRH-mediated effect is therefore low. The prediction rests on a high model score (0.9987) only.
Other top predictions show a similar pattern. Hypertrichosis (generic) has a speculative link through androgen-dependent hair growth, but this fits hirsutism better than congenital hypertrichosis. “Central precocious puberty 1” is probably a genetic subtype of an existing indication, so it is an on-label extension rather than true repurposing. The one publication retrieved, for “physiological sexual disorder”, concerns nafarelin versus danazol for endometriosis pain. It is indirect evidence at best.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No literature is available for the lead prediction. One publication was retrieved for the rank 7 prediction (physiological sexual disorder):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7951404 | 1994 | Clinical study (design not confirmed) | Int J Fertil Menopausal Stud | Compared nafarelin and danazol for dysmenorrhea, dyspareunia and pelvic pain in endometriosis; this is an already approved use and does not directly address a sexual disorder |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02188783 | SYNAREL | Not listed | Not listed |
Safety Considerations
- Knowledge-graph contraindication signals (not label text): hypertensive disorder, hypertension, hyperglycemia, osteoporosis, postmenopausal osteoporosis, diabetes mellitus, diabetic ketoacidosis, substance abuse/dependence, obesity disorder, monogenic obesity.
- Drug interactions: No drug-drug interactions were identified. The only pharmacology record is the expected target, the GnRH1 receptor (GNRHR).
Please refer to the package insert for the official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high (0.9987), but there are no clinical trials or publications, and the mechanism is implausible for a congenital hair-growth disorder. The evidence level is L5.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism-of-action data
- A literature and trial search specific to Ambras syndrome and hypertrichosis
- Review of whether “central precocious puberty 1” should be mapped to the existing approved indication, as it may be a more practical direction than the lead prediction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.